---
id: 125
title: Mycobacterium tuberculosis and Drug-Resistant TB
category: organisms
subcategory: mycobacteria
tags: [TB, tuberculosis, RIPE, MDR-TB, XDR-TB, rifampin, isoniazid]
difficulty: medium
---

## Question

How is drug-resistant TB managed? Use the **"MDR = Resistant to Rifampin + Isoniazid, XDR = MDR + Fluoroquinolone + Injectable"** framework.

## Answer

### **TB Resistance Definitions:**

| Type | Definition | Treatment |
|------|------------|-----------|
| **Drug-Susceptible TB** | Susceptible to all first-line agents | **RIPE × 2 months → RI × 4 months** (6 months total) |
| **Rifampin-Resistant (RR-TB)** | Resistant to rifampin ± other drugs | Treat as **MDR-TB** |
| **MDR-TB** | Resistant to **rifampin + isoniazid** (± others) | **Bedaquiline-based regimen × 18-24 months** |
| **Pre-XDR-TB** | MDR + resistant to **fluoroquinolone** OR **injectable** (amikacin/kanamycin) | **Bedaquiline + linezolid + newer agents × 18-24 months** |
| **XDR-TB** | MDR + resistant to **fluoroquinolone + injectable** | **All-oral regimens (bedaquiline, linezolid, pretomanid, delamanid) × 18-24 months** |

### **MDR-TB Treatment (2024 WHO Recommendations):**

**All-Oral Regimen (Preferred):**

**6-Month BPaL Regimen (newly recommended):**
- **Bedaquiline** 400mg daily × 2 weeks → 200mg 3×/week
- **Pretomanid** 200mg daily
- **Linezolid** 1200mg daily (or 600mg daily if tolerated poorly)
- **Duration: 6-9 months** (much shorter than traditional 18-24 months)
- **Indications:** Non-severe, extensive drug resistance

**Longer MDR-TB Regimen (18-24 months):**
- **Group A (include all 3):**
  - **Levofloxacin** 750-1000mg daily OR **moxifloxacin** 400mg daily
  - **Bedaquiline** 400mg daily × 2 weeks → 200mg 3×/week
  - **Linezolid** 600mg daily (monitor for peripheral neuropathy, optic neuritis, myelosuppression)
- **Group B (add 1-2):**
  - **Clofazimine** 100mg daily
  - **Cycloserine/terizidone** 500-750mg daily
- **Group C (add if needed to reach 4-5 drugs):**
  - **Ethambutol**, **delamanid**, **pyrazinamide**, **amikacin**, **ethionamide**

### **Monitoring and Adverse Effects:**

**Bedaquiline:**
- **QT prolongation** (monitor ECG at baseline, week 2, 4, 12, 24)
- **Hepatotoxicity**
- Avoid with other QT-prolonging drugs

**Linezolid:**
- **Peripheral neuropathy** (dose-dependent, often irreversible)
- **Optic neuritis** (monitor visual acuity monthly)
- **Myelosuppression** (monitor CBC weekly → monthly)

**Fluoroquinolones:**
- **QT prolongation**, **tendon rupture**, **CNS effects**

**Clofazimine:**
- **Skin discoloration** (orange/brown, reversible over months-years)
- **GI effects**

## Key Points

### **Rapid Diagnostics:**
- **GeneXpert MTB/RIF:** Detects TB + **rifampin resistance** in 2 hours (90-95% sensitive)
- **Line probe assays (LPA):** Detect resistance to rifampin, isoniazid, fluoroquinolones, injectables
- **Phenotypic DST:** Gold standard but slow (4-8 weeks)

### **New/Repurposed Drugs:**
- **Bedaquiline (Sirturo):** ATP synthase inhibitor, cornerstone of MDR-TB treatment
- **Pretomanid:** Nitroimidazole, used in BPaL regimen
- **Delamanid:** Nitroimidazole, alternative to pretomanid
- **Linezolid:** Repurposed (originally for Gram-positives), highly effective against TB

### **Treatment Principles:**
- **≥4 effective drugs** (including bedaquiline, linezolid, fluoroquinolone)
- **18-24 months** duration (shorter 6-9 month BPaL if eligible)
- **Directly observed therapy (DOT)** critical
- **Treat in specialized centers** (expert consultation)

### **Latent TB with Drug Resistance:**
- **Contact of MDR-TB:** **Levofloxacin 750-1000mg daily × 6 months** (or fluoroquinolone + ethambutol)
- **No proven regimen** for XDR-TB contacts (close monitoring vs empiric treatment)

### **Clinical Pearls:**
- **MDR-TB:** Resistant to rifampin + isoniazid
- **XDR-TB:** MDR + fluoroquinolone + injectable
- **BPaL regimen:** Bedaquiline + pretomanid + linezolid × 6-9 months (newly recommended)
- **Traditional MDR-TB:** Bedaquiline + linezolid + fluoroquinolone ± others × 18-24 months
- **GeneXpert:** Detects rifampin resistance in 2 hours
- **Linezolid toxicity:** Peripheral neuropathy, optic neuritis (monitor closely)
- **Treat in specialized centers** with ID/pulmonary expertise

## Sources

- [WHO: MDR-TB Guidelines 2024]
- [CDC: Drug-Resistant TB 2024]

## Media

N/A
